Greven J, von Bronewski-Schwarzer B
Department of Pharmacology and Toxicology, Rheinisch-Westfalische Technische Hochschule Aachen, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):496-500. doi: 10.1007/s002100100479.
Moxonidine is a centrally acting antihypertensive agent which has been found to exert its blood pressure lowering effect by interaction with (alpha2-adrenoceptors and imidazoline receptors of the I(1)-type. These receptors have also been demonstrated to be present in the rat kidney. In the present study, clearance and micropuncture techniques were applied to anaesthetized rats to localize the site of action of moxonidine within the nephron. The clearance data show that moxonidine (0.25 mg/kg i.v., followed by a continuous i.v. infusion of 0.25 mg/h) induced a marked increase in urine flow and urinary excretion of sodium, chloride and potassium. The changes in urine flow and urinary solute excretion were accompanied by an enhanced glomerular filtration rate. The micropuncture experiments revealed that moxonidine significantly increased glomerular filtration rate of superficial nephrons, and significantly inhibited fractional reabsorption of fluid, sodium, potassium and chloride by similar amounts (by 9.0%-9.8%) in superficial proximal tubules. Regarding fluid and sodium reabsorption, the proximal effect of moxonidine was continuously weakened by a compensatory increase of reabsorption in the loop of Henle and the subsequent distal nephron segments. The inhibitory effect of moxonidine on fractional proximal potassium reabsorption was completely compensated in the loop of Henle, but the drug induced a net secretion of potassium into the segments lying beyond the early distal tubule, probably as a consequence of the increased tubule fluid and sodium load delivered to them. The experiments have identified the proximal tubule as the principal nephron site where the diuretic action of moxonidine arises. The proximal effect may be related to the increased glomerular filtration rate and to a direct inhibitory interaction of moxonidine with the proximal Na+/H+ exchanger.
莫索尼定是一种中枢性抗高血压药物,已发现它通过与I(1)型α2肾上腺素能受体和咪唑啉受体相互作用来发挥其降压作用。这些受体在大鼠肾脏中也已被证实存在。在本研究中,采用清除率和微穿刺技术对麻醉大鼠进行实验,以确定莫索尼定在肾单位内的作用部位。清除率数据表明,莫索尼定(静脉注射0.25mg/kg,随后以0.25mg/h的速度持续静脉输注)可使尿流量以及钠、氯和钾的尿排泄量显著增加。尿流量和尿溶质排泄的变化伴随着肾小球滤过率的提高。微穿刺实验显示,莫索尼定可显著提高浅表肾单位的肾小球滤过率,并在浅表近端小管中显著抑制液体、钠、钾和氯的分数重吸收,且抑制程度相似(9.0%-9.8%)。关于液体和钠的重吸收,莫索尼定在近端的作用因髓袢及随后的远端肾单位节段重吸收的代偿性增加而持续减弱。莫索尼定对近端钾分数重吸收的抑制作用在髓袢中完全得到代偿,但该药物会导致钾向早期远端小管之后的节段净分泌,这可能是由于输送至这些节段的小管液和钠负荷增加所致。这些实验已确定近端小管是莫索尼定利尿作用产生的主要肾单位部位。近端作用可能与肾小球滤过率增加以及莫索尼定与近端Na+/H+交换体的直接抑制性相互作用有关。